Figure 1From: Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesPercentage growth inhibition by A) dasatinib and B) sorafenib in a panel of melanoma cell lines. Error bars represent the standard deviation of triplicate experiments.Back to article page